Current perspective of severe adverse events and compensation requirements in India

Shekhar Goyal, Akhil Kapoor, Indra Bhadu | International Journal of Clinical Trials | 2014 Aug;1(2):76-77


As per Drug Controller General of India (DCGI), there are clear cut compensation guidelines for clinical trial participants in case of death and injury after amendment in schedule Y (Rule 122DAB – Compensation in case of injury or death during clinical trial). The purpose of these guidelines is to provide Severe Adverse Event (SAE) compensation calculation as well as determination of the ratio of amount in clinical trial injury.

Read full article

Bookmark the permalink.

Comments are closed.